I-Mab stock price target raised to $8 from $6 at Brookline Capital

Investing.com - Brookline Capital Markets raised its price target on I-Mab (NASDAQ:IMAB) to $8.00 from $6.00 on Thursday, while maintaining a Buy rating on the stock. Currently trading at $4.41, the company has shown remarkable momentum with a 429% year-to-date return. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $5 to $7.

The price target increase follows I-Mab’s Q2 2025 financial results and reflects promising Phase 1b dose escalation data for givastomig, the company’s bispecific antibody targeting Claudin 18.2 and 4-1BB, in combination with nivolumab and chemotherapy for gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The $511.7 million market cap company maintains a strong financial position with an "GREAT" overall health score according to InvestingPro analysis, supported by a robust current ratio of 22.8.

Brookline Capital increased its probability of success for givastomig to 35% from 20% based on the Phase 1b data and I-Mab’s strengthened balance sheet following a capital raise in August 2025.

The enrollment of 40 patients in two dose expansion cohorts was completed ahead of schedule in August 2025, with data expected in Q1 2026.

Brookline Capital noted a significant unmet need for targeted, efficacious treatments in gastric cancer, which contributes to the favorable risk-reward profile as givastomig advances through clinical development.

In other recent news, I-Mab has reported significant developments in its cancer treatment trials and corporate strategy. The company announced positive Phase 1b trial results for its bispecific antibody, givastomig, in combination with nivolumab and mFOLFOX6, achieving an 83% objective response rate in treating metastatic gastric cancers. Additionally, I-Mab has completed patient enrollment for the Phase 1b dose expansion cohorts of the givastomig trial ahead of schedule, with topline results expected in the first quarter of 2026. In a strategic move, I-Mab has acquired Bridge Health Biotech Co., Ltd., which will provide the company with upstream rights to the CLDN18.2 parental antibody and eliminate future royalty obligations. This acquisition is expected to enhance the development of givastomig by securing rights to bispecific and multi-specific applications. Furthermore, H.C. Wainwright has reiterated its Buy rating for I-Mab, citing strong trial data and maintaining a price target of $7.00. The recent publication of givastomig’s first-in-human study in Clinical Cancer Research highlighted a 16% objective response rate, which increased to 18% after additional responses were confirmed. These developments underscore I-Mab’s continued progress in advancing its cancer treatment pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.